#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Non-Small Cell Lung Cancer with Estrogen Receptors and ALK Positivity


Authors: L. Žarnayová 1;  V. Kolek 1;  J. Bouchal 2;  J. Ehrmann 3
Authors place of work: Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc 1;  Ústav molekulární a translační medicíny, LF UP v Olomouci 2;  Ústav klinické a molekulární patologie, LF UP a FN Olomouc 3
Published in the journal: Klin Onkol 2018; 31(6): 457-460
Category: Kazuistika
doi: https://doi.org/10.14735/amko2018457

Summary

Background:

Estrogens are steroid hormones that affect a number of physiological functions in cells; these compounds play an irreplaceable role in the reproductive system. Their effects are mediated by the estrogen receptor (ER), of which there are two subtypes – ERα and ERβ. ERs are expressed in regions outside the reproductive system, including bone, brain, intestine, endothelium, kidney, and lung. Expression of ER by lung cancer (LC) cells was first described in the early 1980s. The experimental literature also describes co-expression of ERβ and an epidermal growth factor activating mutation, and the additive antiproliferative effects of anti-estrogens plus tyrosine kinase inhibitors during treatment of lung adenocarcinoma. However, coincident expression of ER and ALK translocation were not decribed. The 4-year survival for generalized non-small cell lung cancer indicates the possibility that both molecular features (ER and ALK positivity) may be a favorable prognostic biomarker for this tumor.

Case:

A 69-year-old patient presented with generalized lung adenocarcinoma that was positive for ERb and the ALK-EML4 fusion gene. The tumor was stage IV. Additional examinations excluded malignancy of the gynecological area. The patient was treated with chemotherapy and a tyrosine kinase ALK inhibitor.

Conclusion:

The role of individual ER subtypes in LC carcinogenesis, and the possible therapeutic effects, is unclear. This is the first documented case of co-occurrence of ALK-EML4 and ERβ in LC.

Key words

non-small cell lung cancer – estrogen receptors – ALK translocation – prognosis – treatment

This work was supported by Ministry of Health of the Czech Republic, grant AZV 16-32318A, and by Ministry of Education, Youth and Sports of the Czech Republic, grant NPU I LO1304.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted: 23. 9. 2018

Accepted: 25. 10. 2018


Zdroje

1. Chaudhuri PK, Thoms PA, Walker MJ et al. Steroid receptors in human lung cancer cytosols. Cancer Lett 1982; 16(3): 327–332.

2. Beattie CW, Hansen NW, Thomas PA. Steroid receptors in human lung cancer. Cancer Res 1985; 45(9): 4206–4214.

3. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 2007; 448(7153): 561–566. doi: 10.1038/nature05945.

4. Cheng TD, Darke AK, Redman MW et al. Smoking, sex, and non–small cell lung cancer in steroid hormone receptors in tumor tissue (S0424). J Natl Cancer Inst 2018; 110(7): 734–742. doi: 10.1093/jnci/djx260.

5. Schwartz AG, Prysak GM, Murphy V et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005; 11(20): 7280–7287. doi: 10.1158/1078-0432.CCR-05-0498.

6. Atmaca A, Al-Batran SE, Wirtz RM et al. The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer. Int J Cancer 2014; 134(10): 2314–2321. doi: 10.1002/ijc.28571.

7. Skjevstad K, Grindstad T, Rakaee Khanehkenari M et al. Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer. Steroids 2016; 113: 5–13. doi: 10.1016/j.steroids.2017.11.010.

8. Ma L, Zhan P, Liu Y et al. Prognostic value of the expression of estrogen receptor β in pacients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 2016; 5(2): 202–207. doi: 10.21037/tlcr.2016.04.04.

9. Nose N, Sugio K, Oyama T et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009; 27(3): 411–417. doi: 10.1200/JCO.2008.18.3251.

10. Raso MG, Behrens C, Herynk MH et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLC and correlates with EGFR mutation. Clin Cancer Res 2009; 15(17): 5359–5368. doi: 10.1158/1078-0432.CCR-09-0033.

11. Mah V, Marquez D, Alavi M et al. Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer 2011; 74(2): 318–325. doi: 10.1016/j.lungcan.2011.03.009.

12. Márquez-Garbán DC, Chen HW, Goodglick L et al. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci 2009; 1155: 194–205. doi: 10.1111/j.1749-6632.2009.04116.x.

13. Márquez-Garbán DC, Mah V, Alavi M et al. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids 2011; 76(9): 910–920. doi: 10.1016/j.steroids.2011.04.015.

14. Hsu LH, Liu KJ, Tsai MF et al. Estrogen adversely affects the prognosis of patients with lung adenocarcinoma. Cancer Sci 2015; 106(1): 51–59. doi: 10.1111/cas.12558.

15. Pietras RJ, Márquez-Garbán DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 2007; 13(16): 4672–4676. doi: 10.1158/1078-0432.CCR-07-1373.

16. Kolkova Z, Noskova V, Ehinger A et al. G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua. Mol Hum Reprod 2010; 16(10): 743–751. doi: 10.1093/molehr/gaq043.

17. Jala VR, Radde BN, Haribabu B et al. Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. BMC Cancer 2012; 12: 624. doi: 10.1186/1471-2407-12-624.

18. Andersson S, Sundberg M, Pristovsek N et al. Insufficient antibody validation challenges oestrogen receptor beta research. Nature Commun 2017; 8: 15840. doi: 10.1038/ncomms15840.

19. Cappuzzo F, Moro-Sibilot D, Gautschi O et al. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. Lung Cancer 2015; 87(2): 89–95. doi: 10.1016/j.lungcan.2014.12.010.

20. Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol 2016; 9: 19. doi 10.1186/s13045-016-0251-8.

Štítky
Dětská onkologie Chirurgie všeobecná Onkologie Pneumologie a ftizeologie Laboratoř

Článek vyšel v časopise

Klinická onkologie

Číslo 6

2018 Číslo 6
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#